{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Novartis AG"},"Symbol":{"label":"Symbol","value":"NVS"},"Address":{"label":"Address","value":"LICHTSTRASSE 35, BASEL, 4056, Switzerland"},"Phone":{"label":"Phone","value":"+41 613241111"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue."},"CompanyUrl":{"label":"Company Url","value":"https://www.novartis.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Shreeram Aradhye","title":"Chief Medical Officer & President-Development"},{"name":"Steffen Lang","title":"President-Operations"},{"name":"Vasant Narasimhan","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}